aTyr Pharma Inc (NASDAQ:LIFE) is trading with a marginal gain in the pre market session on Thursday. The stock is up 24% over the past month.
aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody
- announced the presentation of a poster at the Antibody Engineering & Therapeutics Europe Virtual conference which was held June 8 – 10, 2021. The abstract and poster are available on the conference website.
- The poster presents preclinical findings demonstrating in vitro and in vivo proof-of-concept that the anti-Neuropilin-2 (NRP2) antibody, aNRP2-14, is a high affinity, selective blocker of the Semaphorin 3F/NRP2 interaction. Class 3 Semaphorins are an important set of NRP2 ligands, with recent data implicating their role in sustaining chronic inflammation.
“We are very excited to present these findings for aNRP2-14, which demonstrate the cutting-edge, in-house antibody engineering capabilities that the aTyr team has developed around creating highly specific, fully humanized, monoclonal antibodies targeting NRP2 and the different domains of the receptor,” said Leslie Nangle, Ph.D., Vice President, Research at aTyr. “NRP2 interacts with several different protein ligands individually through these distinct domains to mediate signaling through diverse biological pathways associated with different disease states, and we have created a panel of antibodies targeting these distinct domains.
As of 7, LIFE is trading at $4.82, up 1.05%. So far more than 1K shares have exchanged hands.